In a tweet, the PM shared the news of the Bharat Biotech made Covaxin and SII’s Covishield receiving a green signal from the DCGI for its vaccine rollout
The SII CEO said that an emergency approval is awaited from the DGCI for the Oxford-AstraZeneca Covishield vaccine, post which India can start its COVID immunisation program by January 2021 and hope to come back to normalcy by October next year
The head of the Serum Institute in India which is working on the development of the AstraZeneca based Covishield vaccine in the country has dropped an update about the emergency use approvals. Read on to know.